ES2136198T3 - Composiciones rectales que contienen odansetron en forma de su base libre. - Google Patents

Composiciones rectales que contienen odansetron en forma de su base libre.

Info

Publication number
ES2136198T3
ES2136198T3 ES94918355T ES94918355T ES2136198T3 ES 2136198 T3 ES2136198 T3 ES 2136198T3 ES 94918355 T ES94918355 T ES 94918355T ES 94918355 T ES94918355 T ES 94918355T ES 2136198 T3 ES2136198 T3 ES 2136198T3
Authority
ES
Spain
Prior art keywords
free base
odansetron
methyl
compositions containing
rectal compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94918355T
Other languages
English (en)
Inventor
Isabelle Thielemans
Isabelle Richard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoire Glaxo Wellcome SA
Original Assignee
Laboratoire Glaxo Wellcome SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoire Glaxo Wellcome SA filed Critical Laboratoire Glaxo Wellcome SA
Application granted granted Critical
Publication of ES2136198T3 publication Critical patent/ES2136198T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/02Suppositories; Bougies; Bases therefor; Ovules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

LA INVENCION SE REFIERE A UNA COMPOSICION FARMACEUTICA DE ADMINISTRACION RECTAL QUE CONTIENE 1,2,3,9-TETRAHIDRO-9-METIL-3[(2-METIL-1H-IMIDAZOL-1-IL)-METIL]-4H-CARBAZOL-4-ONA PRESENTADA COMO SU BASE LIBRE O UN SOLVATO FARMACEUTICAMENTE ACEPTABLE DE LA MISMA COMO INGREDIENTE ACTIVO, JUNTO CON UNO O MAS SOPORTES O EXCIPIENTES FARMACEUTICAMENTE ACEPTABLES. TAMBIEN SE DESCRIBEN LOS METODOS PARA LA FABRICACION DE TALES COMPOSICIONES Y SU USO EN EL TRATAMIENTO DE ESTADOS MEDIADOS POR LA ACCION DE 5HIDROXITRIPTAMINA EN RECEPTORES 5-HT{SUB,3}.
ES94918355T 1993-05-25 1994-05-24 Composiciones rectales que contienen odansetron en forma de su base libre. Expired - Lifetime ES2136198T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939310756A GB9310756D0 (en) 1993-05-25 1993-05-25 Compositions

Publications (1)

Publication Number Publication Date
ES2136198T3 true ES2136198T3 (es) 1999-11-16

Family

ID=10736089

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94918355T Expired - Lifetime ES2136198T3 (es) 1993-05-25 1994-05-24 Composiciones rectales que contienen odansetron en forma de su base libre.

Country Status (38)

Country Link
US (1) US5741806A (es)
EP (1) EP0700290B1 (es)
JP (1) JP2965703B2 (es)
KR (1) KR100297212B1 (es)
CN (1) CN1106194C (es)
AP (1) AP544A (es)
AT (1) ATE183643T1 (es)
AU (1) AU680918B2 (es)
BE (1) BE1007158A3 (es)
BR (1) BR1100046A (es)
CA (1) CA2162919C (es)
CO (1) CO4230094A1 (es)
CY (1) CY2411B1 (es)
CZ (1) CZ291041B6 (es)
DE (1) DE69420266T2 (es)
DK (1) DK0700290T3 (es)
EC (1) ECSP941088A (es)
ES (1) ES2136198T3 (es)
FR (1) FR2705569B1 (es)
GB (2) GB9310756D0 (es)
GR (1) GR3031669T3 (es)
HR (2) HRP940315B1 (es)
HU (1) HU227121B1 (es)
IE (1) IE80632B1 (es)
IL (1) IL109749A (es)
IS (1) IS1868B (es)
IT (1) IT1272990B (es)
MY (1) MY111445A (es)
NO (1) NO306448B1 (es)
NZ (1) NZ267415A (es)
PE (1) PE13395A1 (es)
PL (1) PL175578B1 (es)
RU (1) RU2132684C1 (es)
SA (1) SA94150003B1 (es)
SG (1) SG48119A1 (es)
SI (1) SI0700290T1 (es)
WO (1) WO1994027599A1 (es)
ZA (1) ZA943593B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200103054T2 (tr) 1998-06-15 2002-06-21 Sepracor Inc. Apne,bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (+)-norsisapridin kullanımı
EP1087765B1 (en) * 1998-06-15 2005-03-30 Sepracor Inc. Use of optically pure (-) norcisapride in the treatment of irritable bowel syndrome
EP1468685A3 (en) * 1998-06-15 2004-12-15 Sepracor Inc. Use of optically pure (+)-norcisapride for treating apnea, bulimia and other disorders
EP1464333A3 (en) * 1998-06-15 2004-12-15 Sepracor Inc. Use of optically pure (-) norcisapride in the treatment of apnea, bulimia, and other disorders
US6362202B1 (en) 1999-03-02 2002-03-26 Sepracor Inc. Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
US6353005B1 (en) 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
CA2774959C (en) * 2000-08-04 2016-05-31 Dmi Biosciences, Inc. Method of using diketopiperazines and composition containing them

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695578A (en) * 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
SE460359B (sv) * 1984-01-25 1989-10-02 Glaxo Group Ltd 3-imidazolylmetyltetrahydrokarbazoloner, foerfarande foer framstaellning av dessa och en farmaceutisk komposition
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
GB8627909D0 (en) * 1986-11-21 1986-12-31 Glaxo Group Ltd Medicaments
GB8816187D0 (en) * 1988-07-07 1988-08-10 Glaxo Group Ltd Medicaments
GB8914804D0 (en) * 1989-06-28 1989-08-16 Glaxo Group Ltd Process
US5166145A (en) * 1990-09-10 1992-11-24 Alza Corporation Antiemetic therapy

Also Published As

Publication number Publication date
GB2279008A (en) 1994-12-21
IT1272990B (it) 1997-07-01
CA2162919C (en) 1999-07-20
GB2279008B (en) 1997-06-18
HU227121B1 (en) 2010-07-28
ATE183643T1 (de) 1999-09-15
GR3031669T3 (en) 2000-02-29
ZA943593B (en) 1995-02-13
HUT74867A (en) 1997-02-28
GB9310756D0 (en) 1993-07-14
HU9503375D0 (en) 1996-01-29
CZ291041B6 (cs) 2002-12-11
EP0700290B1 (en) 1999-08-25
AU6970994A (en) 1994-12-20
IL109749A (en) 1999-03-12
DE69420266D1 (de) 1999-09-30
ITRM940322A1 (it) 1995-11-24
ITRM940322A0 (it) 1994-05-24
PL311721A1 (en) 1996-03-04
SG48119A1 (en) 1998-04-17
SI0700290T1 (en) 1999-12-31
SA94150003B1 (ar) 2005-04-11
EP0700290A1 (en) 1996-03-13
GB9409835D0 (en) 1994-07-06
IS1868B (is) 2003-05-02
FR2705569A1 (fr) 1994-12-02
HRP940315B1 (en) 2000-12-31
PE13395A1 (es) 1995-05-25
CY2411B1 (en) 2004-11-12
PL175578B1 (pl) 1999-01-29
NO954783D0 (no) 1995-11-24
IE940420A1 (en) 1994-11-30
CA2162919A1 (en) 1994-12-08
CN1106194C (zh) 2003-04-23
AP544A (en) 1996-10-11
IS4168A (is) 1994-11-26
AP9400643A0 (en) 1994-07-31
JPH08510457A (ja) 1996-11-05
CZ308595A3 (en) 1996-06-12
RU2132684C1 (ru) 1999-07-10
MY111445A (en) 2000-05-31
IE80632B1 (en) 1998-10-21
CN1124454A (zh) 1996-06-12
WO1994027599A1 (en) 1994-12-08
US5741806A (en) 1998-04-21
JP2965703B2 (ja) 1999-10-18
ECSP941088A (es) 1994-11-16
AU680918B2 (en) 1997-08-14
HRP970315A2 (en) 1999-04-30
BE1007158A3 (fr) 1995-04-11
IL109749A0 (en) 1994-08-26
NO954783L (no) 1995-11-24
DE69420266T2 (de) 1999-12-09
KR100297212B1 (ko) 2001-10-24
BR1100046A (pt) 1999-11-23
DK0700290T3 (da) 2000-03-13
CO4230094A1 (es) 1995-10-19
FR2705569B1 (fr) 1995-11-10
NO306448B1 (no) 1999-11-08
NZ267415A (en) 1997-10-24
HRP940315A2 (en) 1996-08-31

Similar Documents

Publication Publication Date Title
AR002355A1 (es) Composiciones y metodos para administracion local de agentes farmaceuticamente activos.
AR028833A1 (es) Compuestos inhibidores de metaloproteasas, composiciones farmaceuticas, uso para la manufactura de medicamentos, metodo de tratamiento y procedimiento para su preparacion
UY29825A1 (es) Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones
ES2117015T3 (es) Composiciones que contienen sumatriptan.
CO5271700A1 (es) Composicion farmaceutica que comprende acido 3-[2,4-dimetil-5-(2-oxo-1,2-dihidro-indol-3-ilidenmetil)-1h-pirrol-3-il]-propionico, uno o mas compuestos polihidrocarbilo y un vehiculo farmaceuticamente aceptable
EE05287B1 (et) Tsklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
UY26482A1 (es) Bifenil sulfonamidas como antagonistas de receptores de angiotensina endotelina duales
ES2174129T3 (es) Antagonistas de la hormona de liberacion de la gonadotropina.
PA8580301A1 (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
AR029634A1 (es) Compuestos derivados heterociclicos utiles como agentes anticancerosos, composicion farmaceutica y procedimiento de tratamiento
MXPA04000456A (es) Analogos de prostaglandina como agonistas del receptor ep4.
ECSP941104A (es) Derivados de 2,6 diaminopurina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
ES2147309T3 (es) Composiciones de ondansetron liofilizadas.
ES2186015T3 (es) Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol.
GT200100153A (es) Compuestos de 1,4-dihidropiridina como antagonistas de bradiquinina.
ES2088388T3 (es) Composiciones de macrolido para el tratamiento de trastornos de movilidad gastrointestinal.
AR029941A1 (es) Compuestos utiles para elevar el nivel plasmatico de la hormona del crecimiento y las composiciones farmaceuticas que las contienen
ES2179353T3 (es) Antagonistas muscarinicos.
ECSP055528A (es) Composicion farmaceutica que tiene una distribución y potencia uniforme de farmaco
ES2175089T3 (es) Una combinacion de un inhibidor de la absorcion de 5 - ht con un ant agonista selectivo de 5 ht1a.
AR024998A1 (es) Nuevos retinoides para el tratamiento del enfisema
AR032138A1 (es) Derivados de 6-hidroxi-indazol, una composicion oftalmica, y el uso de dichos derivados para la manufactura de un medicamento para el tratamiento de glaucoma
ES2171911T3 (es) Poliaminas conformacionalmente restringidas y su uso como agentes antineoplasicos.
SE0102055D0 (sv) New Compounds
ES2136198T3 (es) Composiciones rectales que contienen odansetron en forma de su base libre.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 700290

Country of ref document: ES